reason report
one-stop shop comprehens oncolog test pois
bottom line initi coverag
op rate pt upsid current level
ahead vs street sale ahead ebitda
uniqu posit one-stop shop oncolog test
servic provid faster turnaround time vs competit
tech-onli model help grow current level
project deliv sale compound-annual-growth-rate adjust
ebitda growth long-term see valu neo faster-
grow y/i growth biopharma servic busi sale
potenti grow much larger given broader demand
oncolog immunotherapi clinic trial seek biomark screen
assay develop potenti cdx long-term continu
deliv mid-teen growth oncolog test volum account
busi counter year price declin appear
stabil beyond view neo effort develop single-sit
fda-approv multi-gen panel long-term call option much
in-lin strategi bolster biopharma servic busi
one-stop comprehens oncolog test model remain key
market posit hospit pathologist biopharma
partner larg grow one-stop comprehens oncolog
test servic compani market servic hospit oncologist
biopharma believ alreadi hold posit among
immedi peer much broader oncolog test product
market believ posit well hospit biopharma
compani frequent desir one-stop solut test need
biopharma servic opportun remain key long-term growth
outlook view biopharma servic busi neo
revenu today singl import opportun growth
longer-run expect segment continu grow
y/i reach closer revenu mix
year enhanc growth profil via acquisit
current backlog biopharma servic
potenti convert faster manag anticip timelin next
year convert next month
multi-gen test potenti deliv signific upsid
long-term develop single-sit fda-approv multi-
gene test plan take fda approv pathway
potenti entrant alreadi approv foundationon cdx multi-
gene panel categori nation coverag decis ncd
multi-gen test highli valuabl client biopharma
partner believ broaden appeal
submit pre-submiss document multi-gen test
undergo meet fda understand next step toward
eventu approv test
life scienc tool diagnost
net debt total capit
book value-per-share
per share
share outstand mil
compani inform leerink partner llc research
revenu million dilut adjust ep continu oper
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
initi coverag outperform rate price target
upsid current level uniqu posit one-stop oncolog lab
test servic provid deliv top-lin compound-annual-growth-rate adjust ebitda
growth long-term see valu neo faster-grow y/i growth
biopharma servic busi sale potenti grow much larger given
broader demand clinic trial grow cancer immunotherapi trial seek one-stop
shop biomark screen assay develop potenti companion diagnost cdx
long-term continu deliv y/i volum growth oncolog test volum
account busi counter year price declin appear stabil
cost reduct effort impress despit price impact see
posit grow market share even broadli oncolog test beyond neo
effort develop single-sit fda-approv multi-gen panel repres call option us
long-term much in-lin strategi bolster biopharma servic busi
leerink estim factset
one-stop shop high valu broad comprehens oncolog test
busi continu grow take share
one-stop comprehens oncolog test servic compani market servic
hospit oncologist biopharma compani compani posit attract given
uniqu specialti lab servic posit market share market
much broader market oncolog diagnost therapi manag test
believ posit well oncologist hospit biopharma compani frequent desir
one-stop shop solut test need rang immunohistochemistri fish
floresc in-situ hybrid molecular multi-gen panel sequenc unlik
product-focus diagnost compani deliv hospit oncologist lab test
servic broad menu test best class turnaround time compar
product-bas compani provid subset test usual molecular pcr
sequenc driven includ like foundat medicin also
import note serv larg somat test need cancer broadli vs
hereditari test conduct like somat mutat form
domin widespread basi cancer estim diseas
driver mutat hereditari
biopharma servic opportun remain key long-term growth outlook
us biopharma servic busi current account neo
revenu singl import opportun growth longer-run
need precis medicin target therapi grown biopharma compani work
oncolog target drug frequent look diagnost partner help clinic
trial screen patient help develop companion diagnost cancer
immunotherapi trial on-going need companion diagnost identifi
patient therapi
obtain biopharma servic segment acquisit clarient ge
sale also synergi acquisit took time
integr emerg acquisit stronger market posit broader set
offer includ higher growth biopharma servic clarient deliv east
coast west coast lab similar instrument leadership hematolog cancer
solid tumor signific pharma servic busi acquisit allow
consolid two larg oncolog test organ theme believ continu
oncolog test market continu seek opportun expand biopharma
servic busi current backlog biopharma servic hope
convert revenu next year next month
clarient similar compani similar equip similar
infrastructur similar product line similar custom acquisit gain
access similar clinic custom project biopharma custom
specialti cancer focu in-hous capabl offer wide menu test offer
believ continu see growth excess y/i biopharma servic
price stabil year reimburs declin volum drive outlook
deriv major price physician lab fee schedul vs clinic lab fee
schedul clf dictat pama protect access medicar act pama
medicar price alreadi set next year declin year mani case
reimburs also seen steadi declin last year appear
stabil impact medicar price hospit pathologist oncologist
deriv major revenu establish direct contract send
oncolog sampl test
experienc signific price declin larg medicar last year
asp per test declin project price
appear much stabl compar prior year believ price like
continu stabil also import note medicar percentag payment mix
steadili declin establish contract
broader payer also hospit expect price continu declin
rate past neo abil drive mid-teen volum growth clinic diagnost
segment continu grow broaden menu establish posit
market model price declin despit price stabil
believ continu see compound-annual-growth-rate longer-run
multi-gen fda-approv test potenti deliv upsid long-term
work develop single-sit fda-approv multi-gen test plan take
ncd-fda pathway similar foundat medicin pursu dual-path
cms-fda process obtain fda approv decis ncd
fmi receiv final ncd price test believ like provid
valu biopharma clinic trial client via similar multi-gen panel
fda-approv reimburs multi-gen test also use clinic test oper
broaden appeal one-stop shop offer submit pre-submiss
document multi-gen test earlier year undergo meet fda
understand next step eventu approv test
saw cdx ncd-fda approv earlier year step right direct
valu creation advanc cancer test despit ncd appli advanc
cancer recurr relaps refractori metastat advanc stage cancer saw
initi fmi ncd-fda approv posit test present fda approv
iv cdx addit liquid biopsi test beyond solid tumor also posit view
potenti open path neo liquid test road believ current futur
advanc cancer test inclin pursu fda pathway provid nation
coverag immedi medicar popul upon approv clearanc set stronger
ground pursu commerci coverag test
feedback medacorp pathologist oncologist posit overal speak
one-stop shop neo tech-onli model
also spoke number medacorp pathologist oncologist test
servic physician prefer tech-onli tc compon fast turnaround time
help profession pathologist on-staff neolink on-line system deliv result
physician
physician remain confid nation leader test test
tmb tumor mutat burden microsatellit instabl highli valuabl
want send sampl rather build capabl in-hous one medacorp physician
see test volum continu rise given complex establish
built foundat solid reput oncolog test enhanc time
view appear take share test complex might need
compar servic provid physician point unremark servic
slower turnaround time consid labcorp integr oncolog solid
competitor physician also appreci pathologist staff help
find comfort know dedic serv oncologist
pathologist clinic commun physician except one spoke expect see
higher test volum vs hospit practic given
strong feedback see volum increas time see growth
success obtain fda approv multi-gen panel price attract vs
competit
experienc manag team enhanc neo valu time
believ neo success also attribut manag team leadership
doug vanoort appoint ceo bring wealth experi team
addit practic prudent approach grow lab busi vanoort spent sever
year quest well-vers diagnost world vanoort also like investor given
practic conserv approach guidanc overal outlook beyond recent
appoint cfo sharon virag come signific experi commerci payer
head corpor financ chief account offic aetna prior
held variou relat posit includ chief account offic corp head
investor relat bonello also bring signific investor relat sell-sid experi
believ help enhanc profil compani investor
larger share base market cap believ slowli steadili creat
manag team design execut well deliv result beyond
oper team also impress mani year laboratori experi larg
strateg collabor biopharma benefit explor ppd-
june announc global strateg partnership made prefer
oncolog test lab global one largest contract research organ
world signific experi conduct oncolog trial area
wholli focus laboratori offer comprehens set lab servic includ
bioanalyt biomark central lab gmp vaccin scienc expect gener run-
rate revenu least allianc alon end
collabor provid wide rang lab test servic support
oncolog clinic trial activ europ asia collabor leverag
site europ expect open two addit lab
facil one singapor one shanghai
new collabor focus central patholog review well specialti lab servic
includ flow cytometri fish cytogenet molecular assay multiomyx
compani also expect provid client comprehens cdx offer biomark
discoveri regulatori approv commerci compani also aim
provid integr global solut use preclaru system offer real-tim visibl
analyt inform decision-mak
contract add increas number in-contract commerci payer
ad
announc prefer in-network provid august
alreadi wide commerci payer contract place believ volum growth
revenu per test improv place network statu past
impact volum growth collect within day commerci
insur medicar within day hospit believ continu
see upsid gain in-network statu multipl payer across industri
estim tissue-bas tumor profil market current
includ core oncolog test even broadli oncolog test product
market market segment two categori clinic vs research market
broadli hereditari vs somat somat larger portion clinic market account
major advanc cancer test incorpor assay routin
oncolog practic fish molecular profil increasingli becom import
diagnost therapi select therapi manag among cancer patient estim
held around market share compani expect
cancer test market within oncolog test servic market
share within core oncolog test market independ servic compani
exclud lab corp integr oncolog neo market share
alreadi broad rang depth offer portfolio believ
number continu grow neo menu expand continu add capabl
even broadli possibl biopharma servic constitut market
current view becom even larger mix compani within next
neo comprehens test menu provid one-stop shop oncologist pathologist
hospit offer suit test servic includ cytogenet fluoresc in-
situ hybrid fish flow cytometri immunohistochemistri digit imag
molecular test anatom patholog broad test menu incentiv lab outsourc
sampl test base conveni number offer fast
turnaround time neolink portal review patient result support neo clinic staff
interpret data lab typic dont necessari piec place perform
one number test quick turnaround capabl suit offer
make go-to choic oncolog test
neo technic compon tc framework allow differenti
market penetr offer servic flexibl framework allow pathologist
outsourc technic compon diagnost fish choos
either retain profession compon pc outsourc tc-onli model gener
attract proposit allow pathologist outsourc compon process
requir complex tool machineri retain compon allow pathologist
gener revenu local also help pathologist maintain sens control sampl
patient note valu proposit uniqu dont believ
lab servic provid offer capabl extent
cancer diagnost repres grow market new exist biomark tumor
profil continu attract market due medic innov technolog advanc
biomark discoveri incid preval cancer extend
lifespan patient experienc medic advanc
one exampl fda-approv diagnost companion diagnost
wide use maintain highest share test market
immunohistochemistry-bas test detect level express protein
protein allow cancer cell evad immun system express
high physician often opt treat patient inhibitor prevent interact
protein protein help t-cell attack cancer cell
neo portfolio includ dako roch test measur express
nation leader test volum major growth
normal year remark growth
oncolog diagnost market opportun seen case studi non-
one exampl import diagnost biomark measur includ
seen lung cancer accord american lung associ lung cancer
case diagnos earli stage half peopl lung cancer die within
year diagnos local lung cancer surviv rate wherea
metastat lung cancer surviv rate critic diagnos lung cancer earli
stage obvious critic compon physician catch cancer
metastas surviv rate magnitud higher cancer caught later
potenti extend patient lifespan
highlight exampl test non-smal cell lung cancer nsclc paradigm
accord american societi clinic oncolog nsclc repres approxim
lung cancer diagnos year adult expect diagnos
lung cancer expect nsclc case
figur lung cancer breakdown type
offici journal nation comprehens cancer network nccn state
minimum recommend biomark test nsclc includ mutations/fus egfr
marker expect test approv
therapi mutations/fus incid preval indic grow
like see continu increas test volum
nsclc patient squamou non-squam version treat
checkpoint inhibitor combo therapi express high enough
express shown larg portion squamous-cel non-squam cell nsclc posit
express lead effect treatment inhibitor pembrolizumab
addit test could test patient egfr mutat via molecular singl
gene test gene panel multipl gene egfr mutat preval
nsclc patient prior introduct egfr inhibitor therapi overal surviv
patient advanc nsclc less one year deep understand egfr gene
mutat led effect nsclc treatment direct histolog genotyp allow
patient obtain person molecular target therapi note egfr mutat
one mutat one indic valu broader gene panel test
addit test confirm progress tumor figur detail breadth target
nsclc landscap mani target yet address approv therapi
leav lot room test biopharma trial
lung cancer histologysclcnsclc adenocarcinomansclc squamou cellcarcinomansclc larg cell carcinomansclc inc
figur egfr non-smal cell lung cancer diagnost treatment paradigm
signs/ symptomscommon imag testsctscanidentifi mass clinic stagingon first test performedmriif suspicion brain metastasesclassificationtumornodemetastasisstag situnonenonestag iib peribronchi node and/or hilar intrapulmonari lung node primari tumornonestag iiia peribronchi node and/or hilar intrapulmonari lung node primari tumornonestag iiia mediastin lymph node includ subcarin node near lung primari tumornonestag mediastin lymph node includ subcarin node near lung primari tumornonestag iiib mediastin hilar node near lung without primari tumor supraclavicular scalen nodesnonestag mediastin hilar node near lung without primari tumor supraclavicular scalen nodesnonestag ivaani sizemay spread nodeyesstag ivbani sizemay spread nodeyesstag ivstag iiistag iiistag iclin stagingcharacteristicstumor grown lung outer line nearbi site chest wall phrenic nerv heart line primari secondari tumor lobe and/or tumor grown mediastinum heart major blood vessel windpip recurr laryng nerv carina esophagu spine secondari tumor lung differ lobe tumor may grown main bronchu lung inner line caus lung collaps swellingtumor may grown main bronchu lung inner line caus lung collaps swellingtumor may grown main bronchu lung inner line caus lung collaps swellingtumor spread multipl site outsid chest areatumor spread one lung lung line form secondari nodul heart line form secondari nodul fluid around lung heart and/or cancer spread one site outsid chest areatumor grown lung outer line nearbi site chest wall phrenic nerv heart line primari secondari tumor lobe and/or tumor grown mediastinum heart major blood vessel windpip recurr laryng nerv carina esophagu spine secondari tumor lung differ lobe tumor grown lung outer line nearbi site chest wall phrenic nerv heart line primari secondari tumor lobe and/or tumor grown mediastinum heart major blood vessel windpip recurr laryng nerv carina esophagu spine secondari tumor lung differ lobe tumor grown diaphram mediastinum heart major blood vessel windpip recurr laryng nerv carina esophagu spine secondari tumor lung differ lobe tumor grown lung outer line nearbi site chest wall phrenic nerv heart line primari secondari tumor lobetumor may grown main bronchu lung inner line caus lung collaps swellingtumor may grown main bronchu lung inner line caus lung collaps swellingn/an/a neogenom inc
bronchoscopytoto examin airway lung function teststounderstand patient undergo surgeri radiationbiopsycollect sampl pathologisthistolog typingto diagnos type cancer -sclc non-squam cell nsclc squamou cell nsclcbiomark testingto identifi biomark guid treatment help produc best responsesinclud look egfr mutat mutat express levelsnon-metastatictreatmentoptionsstag istag typic respond well surgerymayb chemo stage ibstag iisurgerychemotherapi recommendedstag iiityp requir follow surgerychemotherapyradi therapymolecular patholog -- egfr nsclc nsclc wild typewild therapyplatinum-bas chemotherapi gemcitabin cisplatin necitumumab ema pembrolizumaberlotinib bevacizumab erlotinib afatinib gefitinibcrizotinib also patient ceritinib fda ema platinum-bas chemotherapi bevacizumab option elig patient pembrolizumabmainten therapynecitumumabpembrolizumaberlotinib bevacizumab erlotinib afatinib gefitinibcrizotinib also patient ceritinib fda ema pemetrex continu switch mainten bevacizumab continu therapyimmunotherapi chemotherapi docetaxel ramucirumab afatinibplatinum-bas chemotherapyosimertinib platinum-bas chemotherapyceritinib alectinib failur crizotinib platinum-bas chemotherapyimmunotherapi chemotherapi docetaxel ramucirumab docetaxel nintedanib adenocarinoma ema erlotinib ema platinum-bas chemotherapynon-squam nsclc nsclc treatment option stage iv repres inc
figur frequenc mutat avail therapi nsclc
test enhanc diagnos treatment outcom view oncolog test
becom preval suspect popul believ gener trend toward
comprehens test drive volum test per patient futur narrow
specif subtyp cancer egfr-posit nsclc patient greatli enhanc
respons therapi save system signific cost treatment patient
increas recognit play import role cancer
profil therapi select underscor need develop suitabl cdx
oncolog genom profil market driven increas preval cancer
evolut novel biomark grow interest person medicin
enhanc treatment differ tumor profil among earlier person treatment
approach seen hormon therapi breast cancer patient whose tumor
express estrogen receptor led trastuzumab treat patient
breast cancer paradigm shift led significantli improv patient outcom compar
non-specif chemotherapeut approach use past past decad
signific effort made non-smal cell lung cancer nsclc nsclc patient
first profil egfr gene mutat select patient like respond drug
erlotinib follow egfr mutat patient profil gene rearrang
indic respons drug crizotinib addit mutat rearrang
includ ret kra other includ nccn guidelin
treatment lung cancer use guid patient treatment expect
increas develop biomark exist combo therapi new therapi
drive develop uptak pharma servic busi segment long-term
genealterationfrequ approv approv nsclc molecular approv clinic inc
number compani current compet tumor profil market includ limit
foundat medicin acquir roch roch abbott mp agil
liquid biopsi compani well advanc genom led
abil move panel test character one biomark time
analyz larg number biomark genom profil allow target sequenc rna
dna sampl identifi gene express pattern molecular marker diseas
help improv patient diagnosi evalu diseas prognosi identifi optim therapeut
increas role person medicin clinic applic molecular profil
includ clinic biomark develop patient stratif clinic trial companion
diagnost genom profil clinic research set use develop
molecular understand drug effect among variou patient group variabl gene
express could account failur rate among oncolog therapeut result
see increas role genom profil cdx overal hold potenti drive
therapi select agent target specif patient popul
reimburs appear stabil improv like remain key
driver neo clinic divis long-term
receiv payment contract rate test hospit bill
technic compon tc tech-onli piec test payment though medicar
continu becom increasingli smaller compon direct payment mix
client bill still expos broader medicar popul thu physician fee
schedul remain import overal test asp receiv see declin
past year appear payment stabil key test fish
bill propos rate code appear
improv get paid cytogenet molecular code via clinic lab
fee schedul driven pama estim total impact pama
see effort launch multi-gen test obtain ncd like
remain key upsid driver medicar reimburs long-term recal cdx
multi-gen panel foundat medicin current reimburs medicar ncd
fda-approv would assum similar stabl reimburs
molecular sequenc multi-gen tissu panel long-term complet pre-
submiss document fda like convers fda
immedi futur proceed data submiss next step
figur physician fee schedul hcpc code fish
center medicar medicaid servic
consolid across oncolog practic acquisit practic hospit
like drive increas busi
believ increas consolid commun oncolog practic continu drive
volum growth toward given specialti posit market reput
one-stop shop oncolog test earli practic impact report publish
commun oncolog allianc coa suggest last decad commun
oncolog clinic and/or practic close acquir hospit merg
practic financi struggl coa estim averag commun
oncolog practic close per month rate remain last
year increas complex manag oncolog practic payer burden
system integr continu growth therapi offer privat practic
see higher align hospit vs stand-alon coa believ clinic
close practic acquir hospit practic merg
consolid clearli driven patient volum econom favor hospit
oncolog test continu see commun hospit like outsourc least
tech-onli tc compon increasingli molecular compon find hard keep
rapid chang sequenc technolog infrastructur need maintain
success profit lab program consolid among oncolog practic continu
commun set see increasingli test volum benefit still
client account neo revenu
 molecular code address clf clinic lab fee schedul pama test pricey/i growth inc
figur consolid across oncolog practic continu occur across countri
trend benefit
figur plural commun oncolog practic acquir hospit blue
dot red dot repres closur oncolog practic pink repres
merged/acquir practic half practic acquir merging/b
acquir believ help drive increas test volum
oper fragment industri continu consolid
 oncolog test market highli fragment market consolid
see play compani includ foundat medicin acquir roch
recent counsyl genet acquir continu expect increas number
consolid hereditari test well somat test compani expect
acquisit well believ like look asset enhanc
biopharma servic profil serv increasingli greater number project custom
market deliv growth sale rep biopharma
like ad biopharma busi continu evolv
obtain payment medicar hospit broadli payer
contract contract place essenti provid certainti payment
major neo contract hospit commerci payer seen price
pressur larg medicar past year receiv medicar payment via
physician lab fee schedul expect stabl reimburs given
alreadi stabil slightli certain code vs expect revenu per test
continu declin manag note declin cost per test continu
outpac revenu per test forese futur
experienc signific price declin larg medicar past year
asp per test declin project price
appear much stabl compar prior year believ price like continu
stabil also import note medicar percentag payment mix steadili
declin establish contract broader payer
also hospit expect price continu declin rate
past neo abil drive mid-teen volum growth clinic diagnost segment
off-set price declin establish posit market model
price declin despit price stabil believ continu see
compound-annual-growth-rate longer-run
figur medicar increasingli becom smaller part payer mix
continu help stabil price long-term
one strong point cost structur importantli cost per test clinic
genet oper unit declin sever year impress feat averag
compound-annual-growth-rate believ achiev number factor includ
increas autom lean oper economi scale benefit scale
payer mix clinic testingmedicarecli hospit commerci insuranceother/accruals/pt pay inc
biggest element compani note volum grow investor expect see
lower cost per test accordingli believ still enough headroom reduc cost
biopharma servic present singl import opportun upsid longer-
pharma revenu depend biopharma project contract perform
futur date biopharma project book increas year
year bill revenu increas well year year growth
figur pharma servic revenu breakdown backlog opportun
import compon pharma servic busi backlog growth convers
bill revenu backlog growth repres build-up pharma project
convert futur revenu backlog grow year year
current amount report point backlog
expect convert within next year convert within next
month believ backlog continu increas expect increas
capac lab includ houston address demand beyond potenti acquisit add
capabl biopharma servic compani might lack
work develop single-sit fda-approv multi-gen test plan take
ncd-fda pathway similar foundat medicin pursu dual-path
cms-fda process obtain fda approv decis ncd
fmi receiv final ncd price test believ like provid
valu biopharma clinic trial client via similar multi-gen panel
fda-approv reimburs multi-gen test also use clinic test oper
broaden appeal one-stop shop offer submit pre-
submiss document multi-gen test earlier year undergo meet
fda understand next step eventu approv test
saw cdx ncd-fda approv earlier year step right direct
valu creation advanc cancer test despit ncd appli advanc
cancer recurr relaps refractori metastat advanc stage cancer saw
initi fmi ncd-fda approv posit test present fda approv
iv cdx addit liquid biopsi test beyond solid tumor also posit view
potenti open path neo liquid test road believ current futur
advanc cancer test inclin pursu fda pathway provid nation
coverag immedi medicar popul upon approv clearanc set stronger
foundat pursu commerci coverag test
debt interest rate recent capit rais
debt via term loan facil revolv credit facil capit leas loan
car loan matur rang total long-term debt stand
june believ would prefer maintain debt/ebitda ratio
believ abl de-lev reach model conserv
assum interest rate note due combin term
variabl interest rate fix interest rate interest rate swap agreement import
note final interest rate could potenti lower project rate
term loan facil interest rate swap
term loan facil region bank initi provid term loan revis
june provid addit term loan facil bear interest rate
applic margin libor loan base rate loan plu
adjust libor rate relev interest period
altern base rate determin greatest
 feder fund rate relev interest period per year
combin
applic margin select rang base neo consolid leverag
also enter interest rate swap hedg chang variabl rate
portion term loan facil amend float fix arrang
reduc impact interest rate fluctuat end variabl interest rate
debt swap fix june variabl
interest debt swap fix end
late enter agreement region bank revolv credit
facil june outstand borrow revolv
credit facil net unamort debt issuanc cost
revolv credit facil includ swinglin cover debt sublimit
swinglin loan bear interest altern base rate plu applic margin
due term loan revolv credit facilitycapit leas oblig loanstot lt less interest capit leases- less current portion lt less debt issuanc lt debt inc
revolv facil bear annual interest rate equal applic margin
adjust libor loan base rate loan plu neo option either
adjust libor rate relev interest period
altern base rate determin greatest
 feder fund rate relev interest period per year
combin
applic margin select rang base neo consolid leverag
ratio model interest rate conserv near-term given
frequent chang libor rate
addit term loan facil revolv credit facil outstand capit leas
purchas lab equip offic equip leasehold improv leas expir
variou date weight averag interest rate approxim
leas allow purchas leas properti minim amount upon expir
leas remain leas purchas option fair market valu
proce like use financ acquisit pharma servic
busi view
recent tap equiti capit market gross proce public
offer common stock per share green shoe
option stock repres addit share state intend use
net proce fund growth busi includ acquisit invest
busi enhanc valu
believ neo proce could use fund acquisit add pharma servic
busi hope achiev pharma revenu mix total revenu within
approxim three year believ given neo current capabl
accomplish acquisit inorgan growth current neo pharma servic busi
compris around revenu compar manag annual growth target
pharma servic although manag specif state segment
acquisit believ highli like bolt-on pharma servic acquisit
like enhanc neo capabl mass spectrometri servic autom
molecular precis oncolog
current facil capac potenti expans
broad portfolio molecular oncolog test cancer mutat offer differ
molecular test panel compani clinic custom pharma custom
compani offer single-gen test multi-gen tumor profil call neotyp
cancer profil larger panel test cover gene manag note
facil expans like come like biopharma
compani recent made updat capac flow cytometri program earlier
year open small lab atlanta georgia provid rapid turnaround flow cytometri
servic client area unus capac lab
almost capac avail geneva-rol switzerland facil compani
around capac avail houston expect use biopharma
expans also consider capac avail molecular aliso viejo
littl tighter depart approach capac fort myer fl locat
compani need expand point overal lot avail capac
due avail houston houston also hous overflow
biopharma oper given backdrop inclin think like expand
capac acquisit like biopharma servic get capabl
potenti capac
figur properti locat purpos size
june announc global strateg partnership made prefer
oncolog test lab global one largest contract research organ
world signific experi conduct oncolog trial area
wholli focus laboratori offer comprehens set lab servic includ
bioanalyt biomark central lab gmp vaccin scienc believ strateg
partnership pay signific dividend long-term expect gener run-rat
locationpurposesq ft aliso viejo californialaboratori admin myer floridacorpor hq floridacouri inc
revenu least allianc alon end would
surpris see partnership near- medium-term
collabor provid wide rang lab test servic support
oncolog clinic trial activ europ asia collabor leverag
site europ expect open two addit lab
facil one singapor one shanghai
new collabor focus central patholog review well specialti lab servic
includ flow cytometri fish cytogenet molecular assay multiomyx
compani also expect provid client comprehens cdx offer biomark
discoveri regulatori approv commerci compani also aim
provid integr global solut use preclaru system offer real-tim visibl
analyt inform decision-mak addit compani explor use
combin data asset find effici method identifi appropri patient oncolog
prior june announc alreadi done consider amount work
partnership recent mention allianc current execut phase
alreadi begun make joint sale call propos project note
partnership give opportun grow win bid contract may
potenti abl win stand-alone entiti
inc diagnost test compani focu oncolog compani
offer genet molecular test servic includ cytogenet fluoresc in-situ
hybrid fish flow cytometri immunohistochemistri digit imag molecular
test anatom patholog compani current offer test two busi
segment clinic servic segment pharma servic segment clinic busi
cater patient community-bas pathologist menu offer expect
complementari add-on pathologist practic pharma servic segment
design support pharmaceut compani drug develop effort
busi offer test clinic trial research pharma servic busi expect
becom increasingli import revenu compet peer factor
breadth menu turnaround time profession interpret result nevada
corpor headquart fort myer florida
neo clinic servic busi focus offer wide array oncolog test servic
patient via patholog practic hospit patholog lab academ center
organ order test servic technic compon tc-onli basi
enabl perform profession compon pc obviat need hire lab
technologist purchas expens analyt equip technic compon
outsourc offer client interpret consult servic complet
pc overflow capac upon request base special client need also tailor
servic offer pc tc compon practic prefer direct relationship
oncolog lab
current offer follow test
cytogenet use diagnost prognost predict qualiti
hematolog malign neo cytogenet test identifi chang normal
chromosom pattern allow studi relationship diseas normal
abnorm chromosom
fish test use identifi presenc absenc specif dna sequenc
particular gene chromosom test detect gene alter amplif
delet transloc fish bridg abnorm detect
chromosom dna sequenc level fish technolog use fluoresc probe
bind part chromosom show high degre sequenc similar
cytometri measur characterist cell popul order identifi
malign cell popul diagnost usual perform physician
suspect leukemia lymphoma cytometri also use monitor patient
therapi determin diseas burden increas decreas flow
cytometri cell peripher blood bone marrow aspir lymph node
place label select fluoresc antibodi analyz flow
fluid stream beam light properti measur antibodi includ
size granular fluoresc intens antibodi exhibit sign
fluoresc bind specif cell surfac antigen allow identif
immunohistochemistri digit imag
use diagnos abnorm cell local protein cell tissu section
antibodi bind specif antigen biolog tissu marker
program cell death protein ligand identifi proxi cell death
apoptosi digit imag allow client see util scan slide perform
quantit analysi certain stain segment make clinic oper
molecular test methodolog analyz dna rna structur
function gene molecular level molecular test technolog includ dna
bi-direct sanger sequenc analysi next-gener sequenc
anatom patholog compon allow neo pathologist review surgic
sampl consult basi neo pathologist use expert uniqu
clinic trial research drug discoveri commerci drug develop
compani use diagnost compani prove studi target biomark help
design trial perform necessari test trial help pharmaceut
compani identifi relev biomark recommend platform molecular screen
use discoveri tool informat captur data compet pharma
servic compani base turnaround time project manag qualiti assur
oversight pharma servic revenu consist three differ stream clinic trial
research valid laboratori servic data servic long run expect
pharma servic activ materi companion diagnost cdx opportun
addit within year expect pharma servic segment compris
revenu today pharma servic busi sit total revenu
key addit neo growth came acquisit clarient close decemb
clarient brought synergi east coast west coast lab
similar instrument leadership hematolog cancer solid tumor signific
pharma servic busi acquisit allow consolid two larg oncolog test
organ consolid theme believ continu oncolog test
market clarient similar compani similar product line
similar custom custom acquisit also gain access
similar clinic custom gain project custom
figur percent breakdown clarient clinic oper test busi time
acquisit
acquisit neo growth flatten previou growth
compani place focu retain client order realiz full synergi
full integr process took month sale team integr shorter two-month
time-frame back offic integr six month lab system reprogram
eight month common bill system establish one year lab fulli
integr month post-acquisit acquisit didnt result materi loss
custom combin entiti note less lost due
alon clarient leader digit digit patholog
sophist molecular menu deal acquir number larg clarient
client abl offer broad menu hematolog cancer fish molecular
test similarli didnt extens menu around test previous
clarient brought test tabl allow leverag clarient menu
area wasnt strong creat abil cross-sel grow market share
acquir clarient purchas price sale made
cash million share prefer stock clarient full-year revenu
adjust ebitda bank debt acquisit refinanc
end libor rate consid favor
compet number larg refer lab pure-play comprehens oncolog lab
specialti lab larg academ center hospit closest peer group pure-play
comprehens oncolog lab group includ genoptix csi phenopath variou
region player biggest competitor labcorp integr oncolog servic
provid almost level servic benefit broader network possibl
stabl in-network contract vs still regard one-stop shop model
acut focu oncolog
manag note closest competitor labcorp mayo clinic
genopt small region player labcorp closest compar
similar breadth oncolog offer similar tc/pc model allow
flexibl pc compon mayo clinic decent size oncolog test busi
compet mainli mid-west strongest compet
quest littl less frequent smaller busi cancer side genpath
anoth competitor biorefer lab run genopt oncolog channel
hospit set smaller region player compris bottom rung
view competit advantag peer due breadth test option
offer widest varieti oncolog test servic make go-to choic
hospit practic valu conveni servic focu
breadth offer
neo comprehens portfolio oncolog test attract featur oncologist
pathologist capabl provid suit test includ cytogenet fish flow
cytometri digit imag molecular test anatom patholog hospit want
broad set offer two reason conveni one lab oncolog
test servic perhap importantli one lab could creat sampl
size problem right test fulli serv pathology/oncolog practic
compet turnaround time accord one medacorp specialist turnaround time
except specialist use courier send sampl daili gave
exampl turnaround time expect receiv sampl back soon
hour turnaround time neo test day cytogenet day fish day
molecular test day flow cytometri patholog test servic
one competit advantag bring tc/pc model allow combin
pathologist perform technic profession compon diagnost
process process allow pathologist either outsourc profession
compon retain profession compon in-hous analysi model appeal
lot organ hospital/practic retain right bill profession
compon save cost would take outsourc compon lab like
practic choos retain pc practic could save total cost full tc/pc
servic medacorp specialist spoken appreci flexibl
one medacorp specialist particular note retain pc time
outsourc case typic made tougher case analyz
case neo specialist team analyz sampl consult
high resolut imag technolog appli anatom immunolog
biochem techniqu visual discret compon tissu involv local
antigen tissu stain bond antigen antibodi antibodi
gener specif recognit target antigen antibodi bind antigen
either directli indirectli bind effici could vari creat non-specif bind
limit bind well interact antibodi antigen stain use
chromogen detect involv product color by-product
direct method one-step method involv label antibodi react directli
antigen method simpl rapid sinc use one antibodi sensit lower
due littl signal amplif compar indirect method
figur direct method use one label antibodi bind directli
antigen stain
indirect method use unlabel primari antibodi bind target antigen tissu
first fluorescence-tag secondari antibodi bind primari antibodi method
sensit direct method signal amplifi bind
sever secondari antibodi primari antibodi
import diagnost test play increasingli import role person
therapi assay contain specif antibodi ad target tissu determin
whether antibodi bind antigen insid tissu process catalyz
enzym conjug antibodi locat antigen bind
two molecul detect stain imag either captur manual high
resolut camera autom system ventana roch leica dako
use wide make possibl visual specif antigen stain
help local posit distribut tissu techniqu use mostli
diagnost lab pharma research lab well frequent autom signific
advantag compar test test allow visual distribut
densiti compon relat rest sampl depend
antibodi result either qualit semi-quantit
despit widespread use across research dx applic antibodi variabl
bind effici lead poor signal nois assay addit gener new
antibodi gener take month averag make process highli ineffici
furthermor larg portion antibodi still valid clinic use product larg
volum antibodi gener bottleneck given effort cost involv gener
take hour autom platform longer conduct manual
neo compris revenu price vari test test
test code repres reimburs level technic compon profession
compon global recent propos price portfolio
shown
figur price expect propos schedul
highlight program includ
broad menu antibodi stain current avail in-hous
digit patholog option quantit qualit analysi
highli develop well-staf qa/qc program includ cap profici test
lower repeat rate compar industri standard
fluoresc situ hybrid fish wide use molecular cytogenet techniqu
use fluoresc probe bind chromosom visual subtl sub-microscop
structur featur dna rna target mrna lncrna mirna cell circul tumor
cell tissu sampl identif posit gene detect chromosom
rearrang abnorm analysi interphas chromosom monitor
therapi subtl sub-microscop structur featur dna rna target readili
detect classic cytogenet fish involv three differ technolog cytogenet dna
hybrid fluoresc microscopi process start deriv fluoresc dna
rna probe fragment isol purifi amplifi dna ad fragment
system continu replic bacteria popul preserv fragment
individu sequenc follow fixat hybrid cell sampl circul tumor
cell ffpe frozen tissu sampl fluoresc microscopi use local specif
nucleic acid sequenc chromosom find rna express protein fish
slightli differ use complementari dna complementari rna probe
target sequenc rather target detect protein normal would fish
use identifi mrna dna speci within individu cell chromosom integr
organ function gene also known ish techniqu similar use
identifi abnorm cell oncolog fish probe also gener larger averag
size limit number label bind
figur scheme principl fish test local gene nucleu
neogenom perform high-qual fish test decad capabl
rapidli cost-effect character solid tumor leukemia lymphoma myeloid
disord fish consid sensit detect gener
expens well take hour gener data
fish reimburs multipl code code interest code auto
manual fish test code repres reimburs level technic
compon profession compon global code shown
figur fish reimburs year illustr physician fee schedul
highlight fish program includ
breadth hemefish hematolog probe librari
tech-onli fish option avail probe
enhanc multiplex fish tumor profil neotyp cancer profil
expand aml md plasma cell myeloma panel align newest guidelin
live webinar on-demand train librari neounivers
cytometri wide use semi-quantit techniqu identifi cell popul
analyz frequenc properti cell stain specif fluorochrome-
conjug antibodi frequent use biomed research monitor
immun respons frequenc function differ immun cell subset
measur concurr cytomet central instrument techniqu
follow main compon flow cell laser detector amplif system comput
signal analysi fluoresc particl carri fluid stream laser intercept
flow cell particl pass laser intercept laser light
scatter particl scatter light detect appropri detector via
appropri posit lens detect signal amplifi amplif system
sent comput data analysi comput softwar analyz data output
report show differ paramet includ particl size shape granular frequenc
cytometri compris mid-teen percent neo revenu mix current price
expect drop histor price higher
drop sinc level code flow cytometri test
highlight neogenom cytometri program includ
flow cytometri improv detect low-level abnorm success
small specimen
reduc cell drift increas consist serial test patient via proprietari
option full leukemia/lymphoma phenotyp standard marker
extend marker
cost-effect follow-up panel highli focus marker set monitor known
high-sensit pnh evalu detect limit
complet tech-onli option minim oper error
leader test volum
conduct largest number test countri believ market
share like remain high like despit annual remark growth
saw test recal test commonli use immunotherapi
drug select suitabl patient drug includ keytruda opdivo high
level marker expect benefit increasingli marker
product featur includ tmb use expect volum oncolog
test rise repres slightli revenu
opportun servic test also associ lower margin gener speak
physician hold signific discret choos test would use patient
physician also awar test use specif drug agil dako
background test immun system use number checkpoint protect
healthi tissu cancer checkpoint consist receptor surfac activ
cell correspond ligand ligand program death receptor
protein cell-surfac receptor certain lymphocyt sinc mani cancer
subtyp express higher express level correl higher respons
rate checkpoint inhibitor therapi test wide use cancer
immunotherapi precis therapi identifi patient like respond
checkpoint inhibitor therapi determin person treatment
figur number test number checkpoint-inhibitor
drug test perform use immunohistochemistri formalin-
nsclc
gastric
gastric/gea
recurr
cervic
carcinoma
metastat
molecular test rang one gene multi-gen panel simpl pcr
test tradit sanger sequenc ngs-base comprehens tumor molecular profil
panel given varieti molecular test perform hard interrog price
molecular test molecular test approxim revenu
uniqu provid wide array genet test approach includ singl gene pcr
multi-gen panel also offer tmb tumor mutat burden
mirosatellit instabl test addit transloc deletion/dupl gene
next-gen sequencing-bas approach like provid insight accuraci
detect come multi-gen panel expect continu increas capac
panel see market grow excess near- medium-term
sequenc cost also continu declin see increas cog reduct come
medic interpret long-term simpli reduct sequenc sampl prep cost
molecular also poor reimburs past privat payer place pre-
author requir medicar rate establish clf clinic lab fee
schedul continu declin believ obtain ncd-fda approv multi-gen
panel key step given reimburs uncertainti get fda
approv multi-gen test like see asp molecular improv dramat
would major boost neo molecular franchis
genet instabl tumor mutat burden tmb microsatellit instabl
recent studi shown tumor genom instabl high tumor mutat burden
tmb-h high microsatellit instabl msi-h mismatch repair defici dmmr
posit correl immunotherapi respons us fda approv msi-h tmb-
 phenotyp biomark immunotherapi tumor genom instabl biomark
alreadi use multipl clinic trial surrog select patient differ treatment
option includ singl immunotherapi drug combin immunotherapi drug
combin immunotherapi drug chemotherapi believ molecular test
continu enhanc product featur includ tmb
microsatellit short repeat sequenc dna high vulner dna repair error
high level mean dna repair mechan tumor cell faulti
lead signific number gene mutat make tumor easili recogniz
immun system target immunotherapi
figur mismatch repair defici tumor express percentag
biomark differ cancer subtyp
may fda grant first tissue/site-agnost approv merck keytruda
pembrolizumab patient msi-h dmmr solid tumor present paradigm shift
sinc first time drug approv base result genet biomark test
identif msi-h dmmr tumor major patient
prospect determin use pcr test msi-h test dmmr pcr still gold
standard detect done fragment analysi fa five conserv
concord genet test convent test mmr
demonstr compar pcr fragment analysi msi-ng match
case span cancer type compar mismatch repair statu msi-ng
match case ngs-base test show sensit specif
posit predict valu neg predict valu
figur relationship tumor mutat burden microsatellit instabl
tmb tumor mutat load anoth emerg quantit genom signatur predict
respons immun checkpoint inhibitor consid complementari
cancer patient select tmb measur total number somat mutat per megabas
genom code area mutations/megabas number clinic trial show potenti
tmb identifi patient like benefit immunotherapi across
grow number tumor type foundat medicin recent publish studi
human cancer genom show cgp assay target code genom
accur assess tmb compar sequenc whole exom studi also identifi
tumor type affect eight tissu greater patient high tmb patient
high tmb consid like respond immun checkpoint inhibitor
concord tmb determin immunohistochemistri
recent studi present novarti institut biomed research foundat
medicin compar mutat data cancer genom atla exome-wid
mutat frequenc number mutat panel around gene show strong
posit correl total mutat burden mutat load within subset
gene demonstr feasibl use tmb-h msi-h surrog infer
mutat landscap entir cancer genom sequenc much smaller panel gene
figur tmb immun checkpoint indic therapi respons
tissu biopsi panel cancer-rel gene demonstr clinic util
assess tmb biomark patient respons immunotherapi clinic trial
inhibitor drug opdivo bristol-my squibb keytruda
progression-fre surviv opdivo nivolumab yervoy ipilimumab combin
versu chemotherapi non-smal cell lung cancer nsclc patient tumor
treatment inhibitor keytruda pembrolizumab improv compar
standard-of-car chemotherapi patient mismatch repair-defici microsatellit
base clinic studi use msi-h tmb-h mutations/mb two inhibitor drug
nivolumab pembrolizumab abl expand indic treatment
nivolumab msi-h dmmr metastat progress
fluoropyrimidin oxaliplatin irinotecan
pembrolizumab adult pediatr patient unresect metastat msi-h
dmmr progress follow treatment fluoropyrimidin oxaliplatin
studi shown tmb import predict biomark identifi
popul first-lin cancer patient may benefit inhibitor drug
see benefit neo one-stop shop comprehens oncolog test model offer
product featur tmb like valu even
figur relationship high tmb msi-h high
neogeonom liquid biopsi effort menu
tissu biopsi current consid gold standard diagnosi prognosi therapeut
select howev tissu biopsi limit includ slow turnaround time difficulti
obtain adequ sampl test histor five ten slide total consum
complet diagnost workup tumor compar sampl collect needl
biopsi invas patient undergo serial biopsi procedur hard-to-reach
area especi nsclc pancreat cancer limit view tumor due
intratumor heterogen emerg biolog activ grow tumor
compar tissu biopsi liquid biopsi address sever pain point offer number
benefit make promis altern adjunct method versu standard care clinic
use liquid biopsi creat great interest molecular profil potenti non-
invas altern identifi develop biomark provid action inform
neogeonom cover signific ground alreadi liquid biopsi test
differ genom signatur may reveal import inform cancer type
stage exampl mutat gene egfr fusion kra braf
character lung cancer atm alter character
breast cancer gene altern kra apc braf character colorect
cancer alter character ovarian cancer
one exampl gene-target cancer medicin applic kinas inhibitor imatinib
treatment chronic myelogen leukemia cml featur balanc
chromosom transloc mutat frequent measur via multi-gen panel
worth note fda-approv gene mutat drug develop potenti
measur liquid biopsi
neo expand menu liquid biopsi test
neogenom see liquid biopsi test servic part pharma servic offer new
therapeut diagnost test expand area futur growth compani continu
lead innov expand test menu liquid biopsi test work
pharmaceut compani clinic trial lead edg develop field
oncolog develop next-gener sequenc technolog enabl
interrog genom broader scale liquid biopsi liquid biopsi test servic
neogenom appli technolog monitor tumor-specif mutat cell-fre circul
dna cell-fre circul rna cfdna/cfrna identif mutat plasma
urin patient cancer
provid client advanc servic possibl expand
robust comprehens menu non-invas liquid biopsi assay cover solid
hematolog tumor rang interrog individu gene whole genom
analysi expect market go grow near term mainli prostat cancer
multiplex panel profil due larg patient popul wide applic test
neolab prostat cancer test first non-invas liquid biopsi measur gene
express level blood urin analyz result algorithm contain
biomark data along age spsa detect patient risk develop
clinic signific prostat cancer util liquid biopsi result reduc need
unnecessari biopsi identifi patient need addit evalu and/or
prostat biopsi hematolog multiplex panel profil wide use number
lymphocyt leukemia cll mantl cell lymphoma mcl diffus larg b-cell lymphoma
dlbcl solid tumor multiplex panel profil use monitor therapi respons
detect tumor heterogen predict earli diseas relaps multiplex panel also
provid import inform develop treatment manag strategi
underli diseas current futur clinic research project
neogenom neolab liquid biopsi platform provid comprehens menu non-invas
cfdna cfrna liquid biopsi assay target tumor profil singl gene sequenc
liquid biopsi test expect
minim procedur invas patient risk
maxim potenti accuraci sensit patient genom footprint character
reduc test turnaround time enabl frequent monitor therapi effect
improv sampl avail eas sampl collect
neolab liquid biopsi platform current offer solid tumor test hematolog
tumor test liquid biopsi platform import long-term growth potenti
neolab solid tumor liquid biopsi offer test help patient metastat solid tumor
cancer avoid repeat tissu biopsi still abl get assess current
mutat profil tumor liquid biopsi test panel use ctdna ctrna combin
assess mutat profil avoid issu intra- inter-tumor heterogen
sampl bia due oper allow potenti detect low-level clone clonal
evolut enabl frequent serial test allow quantit assess tumor
progress trend diagnos popul
neolab hematolog tumor liquid biopsi offer assay four multiplex profil
single-gen analys detect measur critic biomark peripher
blood plasma patient known suspect hematolog cancer cell-fre circul
hematolog tumor nucleic acid analyz patient bone marrow diseas
worth note neolab liquid biopsi test clia lab test without fda
pma approv far liquid biopsi test receiv breakthrough devic
design fda blood-bas cancer diagnost assay papgen earli
ovarian pancreat cancer detect pgdx elio plasma resolv cell-fre dna assay
person genom diagnost foundationact test foundat medicin guardant
health liquid biopsi assay grant expedit access pathway design
manag well regard investor manag made key
member deep industri knowledg experi neo ceo doug vanoort bring
relev leadership experi bonello bring dynam sell-sid
knowledg base tabl analyst reput diagnost servic
product franchis key manag member bring depth sharpen
skillset commerci healthcar model key player list
dougla vanoort chief execut offic chairman board director sinc
octob prior becom ceo mr vanoort spent seven month chairman
board director execut chairman interim chief execut offic join mr
vanoort gener partner privat equiti firm found manag partner
ventur capit firm mr vanoort serv variou posit corn
incorpor spin-off compani inc serv
senior vice-president oper quest newli form nyse-trad compani
held senior execut posit corn life scienc inc includ
execut vice-president corn life scienc revenu spun-off public
transact creat covanc inc mr vanoort serv
variou execut posit corn incorpor includ director merger
acquisit mr vanoort current serv member board director sever
privat held compani princip owner privat held retail hardwar store chain
mr vanoort graduat bentley univers
bonello vice presid strategi corpor develop ir mr bonello vice-president
strategi corpor develop ir inc prior join
mr bonello spent nearli year healthcar equiti analyst cover diagnost servic
product stock piper jaffray wachovia secur craig-hallum capit group mr
bonello also senior vice-president ir labcorp earn ba carleton colleg
mba kellogg school manag northwestern univers
sharon virag chief offic ms virag join neogenom cfo
member financi account standard advisori council fasac group advis
account standard board fasb matter relat board project
agenda priorit prior ms virag serv head corpor financ chief
account offic aetna held variou relat posit includ chief
account offic corp global control posit sever
busi assist corpor control ms virag
public compani account oversight board pcaob
robert shovlin presid clinic servic divis mr shovlin join chief
oper offic serv presid clinic servic divis previous
serv chief develop offic bostwick laboratori lead provid anatom
patholog test servic serv sever posit increas
respons ultim presid ceo aureon bioscienc inc venture-back
diagnost compani focus develop novel proprietari prostat cancer test mr
shovlin also serv execut director anatom patholog director manag
held sale leadership posit dianon
system mr shovlin serv captain infantri offic unit state
marin corp serv platoon command compani
command battalion marin instructor staff platoon command
basic school receiv bachelor degre pennsylvania state univers
financ rutger univers
georg cardoza presid pharma servic divis mr cardoza appoint presid
pharma servic march sinc novemb serv
cfo prior current posit mr cardoza cfo protocol integr direct
market mr cardoza spent year includ year still
part corn inc corn inc work corn life scienc divis
sever acquisit pharma servic space acquisit form piec
covanc spun time quest mr cardoza work
close pharmaceut servic clinic trial divis combin
clinic trial arm clarient inc acquir gener electr healthcar
steven brodi ph facmg vice-president oper dr brodi vice-president oper
also laboratori director europ previous serv compani presid
pharma servic divis chief scientif offic director biopharma oper
laboratori director director molecular cytogenet prior join dr
brodi serv senior director cytogenet assist director molecular genet
scientif director matern serum screen specialti laboratories/quest diagnost
valencia ca dr brodi held varieti research clinic posit nation
institut nih univers new mexico school medicin ucla david geffen
school medicin dr brodi receiv genet train ucla/cedar-sinai medic
center medic genet train program lo angel ca receiv ph
school medicin complet clinic genet train cytogenet molecular
genet ucla
given grow oncolog specialti test nich oper breadth
offer market penetr thu far believ trade premium
current ev/sal multipl view current valuat slightli under-valued
compar lab test servic test product provid group lh
ghdx htgm trade ev/sal
valu ev/sal multipl premium peer group averag
ev sale result multipl believ warrant
premium peer group given growth potenti expand market uniqu posit
oncolog test use ev sale multipl sale arriv
pt
figur compar compani analysi valuat
inc compar compani analysispricesal servic compani corpor america health molecular diagnost servic compani peer multipleimpli impli inc
compet larg lab oper labcorp other
lab offer similar portfolio servic could problemat term
brand recognit market adopt differenti servic speed
reliabl failur continu effect manag relationship could hamper neo abil
realiz market share
expect consolid continu theme within lab test space howev
market could shift larger compani may becom less acquisit may
less interest acquir compani grow brand one scenario consolid
potenti acquisit market turn chanc may taken one
larger lab test compani may slim
expect high volum growth clinic genet oper pharma servic
test busi failur achiev optim market share could lead drop test
volum grow test volum high enough could materi impact
revenu valuat may affect
oncolog test market dynam industri new test methodolog
biomark discoveri chang rapid pace compani like foundat medicin
grail guardant work liquid biopsi exist potenti threat neo
market posit technolog may chang physician test prefer may chang
guidelin recommend regulatori bodi may updat guarante
abl withstand materi chang
part valuat depend neo abil retain competit grow market share
one way possibl acquisit certainti come
time structur gener natur acquisit sinc imposs predict
acquisit occur exact dynam said acquisit caution investor
weight invest hope acquisit
companion diagnost could growth driver sector long-term cdx
opportun predict subject factor beyond neo control failur
materi certain project cdx opportun could neg effect investor
outlook compani
good sold
amort intang
total expens incom
sg sale
 sale
oper expens sale
compani report leerink partner estim
